Koyfin Home > Directory > Health Care > Acceleron Pharma > EBITDA Margin

Acceleron Pharma EBITDA Margin Chart (XLRN)

Acceleron Pharma annual/quarterly EBITDA Margin from 2012 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Acceleron Pharma EBITDA Margin for the quarter ending June 06, 2020 was $-45m a -2,419.69% increase of 1,094m year over year
  • Acceleron Pharma EBITDA Margin for the last 12 months ending June 06, 2020 was $-161m a -132.35% increase of 213m year over year
  • Acceleron Pharma Annual EBITDA Margin for 2019 was $-179m a -381.62% increase of 683m from 2018
  • Acceleron Pharma Annual EBITDA Margin for 2018 was $-862m a 7.84% decrease of -68m from 2017
  • Acceleron Pharma Annual EBITDA Margin for 2017 was $-795m a 70.81% decrease of -563m from 2016
Other Margins & Efficiency Metrics:
  • Acceleron Pharma Return on Capital % for the quarter ending September 09, 2018 was -23.05 a 14.16% decrease of -3.26 year over year
  • Acceleron Pharma Return on Equity % for the quarter ending September 09, 2018 was -35.54 a 13.15% decrease of -4.68 year over year
View Chart On Koyfin

Quarterly XLRN EBITDA Margin Data

06/2020$-45m
03/2020$-1,164m
12/2019$-62m
09/2019$-1,139m
06/2019$-73m
03/2019$-1,434m
12/2018$-941m
09/2018$-892m
06/2018$-785m
03/2018$-827m

Annual XLRN EBITDA Margin Data

2019$-179m
2018$-862m
2017$-795m
2016$-232m
2015$-330m
2014$-337m
2013$14m
2012$-181m
2011$52m